What's breaking now, across thousands of outlets.
(RTTNews) - Biotechnology company Cerenome, Inc. (CNSY) announced on Wednesday that its CNSide Diagnostics unit has entered into a national in-network laboratory provider agreement with Aetna covering its cerebrospinal fluid tumor cell enumeration and molecular profiling tests.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
Marvell's acquisition of Lumentum will create an optical networking juggernaut.
Enterprise pullbacks weighed on results as CTV and AI channels gained ground.
Management outlined three Phase III readouts and a new Middle East licensing deal.
A recurring subplot of President Trump's term has been a desire to replace Biden appointees to the powerful Federal Reserve Board of Governors — even ahead of their terms ending — with allies. That effort now looks dead in the water.
The Horizon International Equity ETF is seeing unusually high volume in afternoon trading Wednesday, with over 304,000 shares traded versus three month average volume of about 29,000. Shares of FRGN were up about 1.5% on the day. Components of that ETF with the highest volume
